ISM5411 is an oral, PHD 1/2-specific inhibitor that facilitates the treatment of IBD by inducing the expression of gut barrier protective genes. ISM5411 is Insilico Medicine’s fifth AI-driven drug ...

Scores on a broad panel of blood metabolomic markers may predict inflammatory bowel disease (IBD) up to 10 years before onset, indicated a new study that leveraged population data from three countries ...

Most inflammatory bowel disease (IBD) therapies — particularly biologic agents — appear safe in patients with chronic kidney disease (CKD); however, caution is required with certain conventional ...

Inflammatory bowel disease (IBD) patients who are resistant to or cannot tolerate conventional treatment now have a more flexible biologics option available to them. Entyvio (generic name vedolizumab) ...